Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Or Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)”

6 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 6 of 6 results

Early research (Phase 1)Study completedNCT03703167
What this trial is testing

Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL)

Who this might be right for
Primary Central Nervous System Lymphoma (PCNSL)Secondary Central Nervous System Lymphoma (SCNSL)
Memorial Sloan Kettering Cancer Center 25
Early research (Phase 1)Ended earlyNCT05242146
What this trial is testing

GB5121 in Adult Patients With Relapsed/Refractory CNS Lymphoma

Who this might be right for
CNS Lymphoma
GB005, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. 12
Testing effectiveness (Phase 2)UnknownNCT04457869
What this trial is testing

F520 in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Secondary Central Nervous System Lymphoma (SCNSL)

Who this might be right for
Primary Central Nervous System LymphomaSecondary Central Nervous System Lymphoma
Shandong New Time Pharmaceutical Co., LTD 43
Testing effectiveness (Phase 2)Active Not RecruitingNCT05485753
What this trial is testing

GNC-038, a Tetra-specific Antibody, in Patients With Central Nervous System Lymphoma (PCNSL) and Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)

Who this might be right for
Primary Central Nervous System LymphomaSecondary Central Nervous System Lymphoma
Sichuan Baili Pharmaceutical Co., Ltd. 7
Testing effectiveness (Phase 2)Study completedNCT02315326
What this trial is testing

Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)

Who this might be right for
Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL)Or Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)
Memorial Sloan Kettering Cancer Center 93
Testing effectiveness (Phase 2)Looking for participantsNCT04792489
What this trial is testing

DALY II USA/ MB-CART2019.1 for DLBCL

Who this might be right for
Refractory Diffuse Large B Cell Lymphoma (DLBCL)Relapsed Diffuse Large B Cell LymphomaHigh Grade B-cell Lymphoma (HGBCL)+5 more
Miltenyi Biomedicine GmbH 248